Clinical Trial Update: The MIGHT Trial - An Exploratory Clinical Trial of IVIG in Anti-HMGCR Immune Mediated Necrotizing Myopathy [Phase 2]

View source ↗

Summary

Phase 2 exploratory trial investigating intravenous immunoglobulin (IVIG) for anti-HMGCR immune-mediated necrotizing myopathy; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hmg-coa Reductase Immune-mediated Necrotizing Myopathy

Drugs mentioned

• Intravenous immunoglobulin (IVIG) (intravenous immunoglobulin)

Snippet

Sponsor: University of Alabama at Birmingham | Conditions: Anti-3-hydroxy-3-methylglutaryl-CoA Reductase (HMGCR) Immune-Mediated Necrotizing Myopathy | Phase 2 | Status: RECRUITING